NEGXF (NexgenRx) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 03, 2026)


NEGXF NexgenRx Inc NEGXF
51 GF Score
Price $0.33
GF Value $0.27
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is NexgenRx Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

NexgenRx's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

NEGXF vs VEEV, BTSG, TEM: Margin of Safety % (DCF FCF Based) Comparison

For the Health Information Services subindustry, NexgenRx's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NexgenRx Margin of Safety % (DCF FCF Based) vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where NexgenRx's Margin of Safety % (DCF FCF Based) falls into.


NEGXF
51GF Score
NexgenRx Inc NEGXF
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NexgenRx (NEGXF) Overvalued in 2026?

Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued. The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27. GuruFocus considers NexgenRx to be Modestly Overvalued.

Key valuation signals for NEGXF:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NexgenRx Business Description

Other Exchanges NXG:Canada
Address 191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
51GF Score

Get the complete analysis for NEGXF

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.27
GF Value